Scientific Reviews
Product Guides
Blogs
Topics
Targeted therapy! The Capetin Prize winning "Click Chemistry" can be used like this!Targeted therapy! The Nobel Prize winning "Click Chemistry" can be used like this!2025-02-06
17 Results for "
complement alternative pathway
" in MedChemExpress (MCE) Product Catalog:
Products (17)
17 Results for "complement alternative pathway" in MCE Product Catalog:
13
Target:
Iptacopan (LNP023) is an effective and orally-active highly selective factor B inhibitor with an IC50 value of 10 nM and KD of 7.9 nM. Iptacopan exerts a proximal effect in the complement cascade reaction, preventing the destruction (hemolysis) of red blood cells in PNH and the damage of renal cells in IgAN and C3G. Iptacopan can be used for the study of complement-mediated diseases, particularly paroxysmal nocturnal hemoglobinuria (PNH), primary immunoglobulin A nephropathy (IgAN), and complement 3 glomerulopathy (C3G) .
13
13 Publications Verification
別名: LNP023 hydrochloride
Target:
Iptacopan (LNP023) hydrochloride is an effective and orally-active highly selective factor B inhibitor with an IC50 value of 10 nM and KD of 7.9 nM. Iptacopan hydrochloride exerts a proximal effect in the complement cascade reaction, preventing the destruction (hemolysis) of red blood cells in PNH and the damage of renal cells in IgAN and C3G. Iptacopan hydrochloride can be used for the study of complement-mediated diseases, particularly paroxysmal nocturnal hemoglobinuria (PNH), primary immunoglobulin A nephropathy (IgAN), and complement 3 glomerulopathy (C3G) .
5
Target:
研究分野:
Danicopan (ACH-4471), a selective and orally active small-molecule factor D inhibitor, shows high binding affinity to human Factor D with Kd value of 0.54 nM. Danicopan (ACH-4471) inhibits alternative pathway of complement (APC) activity, has potential to block the alternative pathway of complement in paroxysmal nocturnal hemoglobinuria (PNH) and atypical hemolytic uremic syndrome (aHUS) .
製品番号: HY-P99965
CAS 番号: 1917321-26-6
別名: SKY59; RO7112689; RG-6107
Target:
別名: BCX9930
Target:
研究分野:
Pelecopan (BCX9930) is a potent, selective, orally active inhibitor of complement factor D with an IC50 value of 14.3 nM. Pelecopan can target factor D to prevent both intravascular and extravascular hemolysis in PNH. Pelecopan also be used for other alternative pathway (AP) mediated diseases .
製品番号: HY-P990952
CAS 番号: 2527079-60-1
別名: OMS906
Target:
研究分野:
FD-IN-1 (Compound 12) is an orally bioavailable and selective factor D (FD) inhibitor with an IC50 of 12 nM. Complement FD, a highly specific S1 serine protease, plays a central role in the alternative complement pathway of the innate immune system. FD-IN-1 also inhibits factor XIa (FXIa) and Tryptase β2 with IC50s of 7.7 and 6.5 µM, respectively .
製品番号: HY-P99298
CAS 番号: 1278466-20-8
別名: RG 7417; TNX 234; Anti-CFD Recombinant Antibody
Target:
研究分野:
製品番号: HY-172090
CAS 番号: 3103336-29-1
Target:
研究分野:
MASP-2-IN-1 (Compound 77) is a selective MASP-2 inhibitor with an IC50 of 0.0114 μM, and an IC50 of 13.2 μM against MASP-3. MASP-2-IN-1 inhibits the catalytic activity of MASP-2 in the lectin complement pathway. MASP-2-IN-1 is applicable to the research of immune diseases .
Target:
研究分野:
Complement factor D-IN-2 is an inhibitor of complement factor D extracted from patent WO2015130838A1, compound 190. Complement factor D-IN-2 targets factor D and inhibits the complement cascade at an early and essential point in the alternative complement pathway. Complement factor D-IN-2 can be used for the research of autoimmune diseases .
製品番号: HY-200854
CAS 番号: 2447007-60-3
別名: LNP023 hydrochloride hydrate
Target:
Iptacopan (LNP023) hydrochloride hydrate is an effective and orally-active highly selective factor B inhibitor with an IC50 value of 10 nM and KD of 7.9 nM. Iptacopan hydrochloride hydrate exerts a proximal effect in the complement cascade reaction, preventing the destruction (hemolysis) of red blood cells in PNH and the damage of renal cells in IgAN and C3G. Iptacopan hydrochloride hydrate can be used for the study of complement-mediated diseases, particularly paroxysmal nocturnal hemoglobinuria (PNH), primary immunoglobulin A nephropathy (IgAN), and complement 3 glomerulopathy (C3G) .
製品番号: HY-N12265
CAS 番号: 108885-62-7
Category:
Human Gut Microbiota Metabolites Viola philippica Cav. Microorganisms Terpenoids Sesquiterpenes Violaceae Plants Endogenous metabolite
Target:
製品番号: HY-P992456
Target:
製品番号: HY-P992463
Target:
研究分野:
製品番号: HY-P991022
CAS 番号: 2842046-67-5
別名: NM8074
Target:
研究分野:
製品番号: HY-P990955
CAS 番号: 2839652-75-2
別名: ADX-097
Target:
研究分野:
製品番号: HY-127105B
CAS 番号: 1644670-38-1
別名: LNP023 TFA
Target:
Iptacopan (LNP023) TFA is an effective and orally-active highly selective factor B inhibitor with an IC50 value of 10 nM and KD of 7.9 nM. Iptacopan TFA exerts a proximal effect in the complement cascade reaction, preventing the destruction (hemolysis) of red blood cells in PNH and the damage of renal cells in IgAN and C3G. Iptacopan TFA can be used for the study of complement-mediated diseases, particularly paroxysmal nocturnal hemoglobinuria (PNH), primary immunoglobulin A nephropathy (IgAN), and complement 3 glomerulopathy (C3G) .
- 1
-
-
Protocols
Targeted therapy! The Capetin Prize winning "Click Chemistry" can be used like this!Targeted therapy! The Nobel Prize winning "Click Chemistry" can be used like this!A suitable model is crucial in drug screening experiments. Organs can mimic the three-dimensional functional structure of internal organs, have similar spatial organization to corresponding organs, maintain some key characteristics, and reproduce some physiological functions. They are widely used for modeling and personalized drug screening physiological functions.2025-02-06
